Company Name, Ticker, Industry, else..

Gri Bio Inc (NASDAQ: GRI)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Gri Bio Inc 's

Name: Gri Bio Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GRI Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Gri Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.47 %, recorded in the same quarter.

• List of GRI Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Gri Bio Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< GRI Stock Performance Comparisons

<< See the full list of GRI competitors

*Market share is calculated based on total revenue.

GRI's Stock Performance relative to its Competitors

Publicly Traded Peers of Gri Bio Inc

Galapagos Nv
Share Performance

-1.01%

This Quarter

Galapagos Nv

Profile

Galapagos Nv's business model is centered around the development and commercialization of innovative medicines. They leverage their expertise in drug discovery and development to collaborate with partners in the healthcare industry, focusing on the advancement of novel therapies to address unmet medical needs.

More about Galapagos Nv's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,943.962 mill.	$ 1,245.718 mill.	$ 359.390 mill.

Medicinova Inc
Share Performance

+6.57%

This Quarter

Medicinova Inc

Profile

Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.

More about Medicinova Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 71.341 mill.	$ 0.597 mill.	$ -11.720 mill.

Medicure Inc
Share Performance

0.00%

This Year

Medicure Inc

Profile

Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.

More about Medicure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ 22.103 mill.	$ -5.436 mill.

Mereo Biopharma Group Plc
Share Performance

-44.88%

This Year

Mereo Biopharma Group Plc

Profile

Mereo Biopharma Group Plc's business model focuses on the development and commercialization of innovative therapeutics for rare diseases.

More about Mereo Biopharma Group Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 45.078 mill.	$ - mill.	$ -35.710 mill.

Nektar Therapeutics
Share Performance

-3.42%

Over The Past 5 Days

Nektar Therapeutics

Profile

Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.

More about Nektar Therapeutics's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,393.007 mill.	$ 54.589 mill.	$ -157.127 mill.

62 more competitors available

Sources: Gri Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, August 31, 2026 11:26 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gri Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.